Evaluation of an Internet-based disease trajectory decision tool for prostate cancer screening

Value in Health

Volumn 12, Issue 1, 2009, Pages 101-108

  Bhatnagar, Vibha ^a,b,c   Frosch, Dominick L ^d   Tally, Steven R ^b   Hamori, Charles J ^e   Lenert, Leslie ^f   Kaplan, Robert M ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e KAISER PERMANENTE   (United States)

^f CDC   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Decision aids; Patient preferences; Prostate cancer; Prostate cancer screening; Utility weights

Indexed keywords

ARTICLE; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; HUMAN; INTERMETHOD COMPARISON; INTERNET; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE;

CHRONIC DISEASE; DECISION SUPPORT TECHNIQUES; HUMANS; INTERNET; MALE; MASS SCREENING; MIDDLE AGED; PATIENT PREFERENCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TIME FACTORS;

EID: 58849136772     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00407.x     Document Type: Article

References (58)

1. Sepucha K, Ozanne E, Silvia K, et al. An approach to measuring the quality of breast cancer decisions. Patient Educ Couns 2007 65 : 261 9.
2. Zeliadt SB, Ramsey SD, Penson DF, et al. Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer 2006 106 : 1865 74.
3. Denberg TD, Melhado TV, Steiner JF. Patient treatment preferences in localized prostate carcinoma: the influence of emotion, misconception, and anecdote. Cancer 2006 107 : 620 30.
4. Sepucha KR, Fowler FJ Jr., Mulley AG Jr. Policy support for patient-centered care: the need for measurable improvements in decision quality. Health Aff (Project Hope) 2004 (Suppl. Web Exclusives VAR54 62.
5. Elkin EB, Cowen ME, Cahill D, et al. Preference assessment method affects decision-analytic recommendations: a prostate cancer treatment example. Med Decis Making 2004 24 : 504 10.
6. Stanford JL Sr., Coyle LM, Cerhan J, et al. Prostate cancer trends 1973-1995. SEER Program, National Cancer Institute, NIH Pub, 1999 No. 99-4543.
7. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003 169 : 517 23.
8. Hall HI, Satariano WA, Thompson T, et al. Initial treatment for prostate carcinoma in relation to comorbidity and symptoms. Cancer 2002 95 : 2308 15.
9. Frosch DL, Bhatnagar V, Tally S, et al. Internet patient decision support: a randomized controlled trial comparing alternative approaches for men considering prostate cancer screening. Arch Intern Med 2008 168 : 363 9.
10. Radosevich DM, Partin MR, Nugent S, et al. Measuring patient knowledge of the risks and benefits of prostate cancer screening. Patient Educ Couns 2004 54 : 143 52.
11. Lenert LA, Michelson D, Flowers C, Bergen MR. IMPACT: an object-oriented graphical environment for construction of multimedia patient interviewing software. Proceedings/the Annual Symposium on Computer Application in Medical Care. 1995 : 319 23.
12. Harris R, Lohr KN. Screening for Prostate Cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002 137 : 917 29.
13. Bunting PS. Screening for prostate cancer with prostate-specific antigen: beware the biases. Clin Chim Acta 2002 315 : 71 97.
14. Zoorob R, Anderson R, Cefalu C, Sidani M. Cancer screening guidelines. Am Fam Physician 2001 63 : 1101 12.
15. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003 21 : 383 91.
16. Ransohoff DF, McNaughton Collins M, Fowler J, Floyd J. Why is prostate cancer screening so common when the evidence is so uncertain? a system without negative feedback. Am J Med 2002 113 : 663 7.
17. Partin AW, Hanks GE, Klein EA, et al. Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology (Williston Park) 2002 16 : 1218 24 discussion 1224, 1227-8 passim.
18. Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 2002 29 : 173 81.
19. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002 137 : 917 29.
20. Bhatnagar V, Kaplan RM. Treatment options for prostate cancer: evaluating the evidence. Am Fam Physician 2005 71 : 1915 22.
21. Bhatnagar V, Stewart ST, Bonney WW, Kaplan RM. Treatment options for localized prostate cancer: quality-adjusted life years and the effects of lead-time. Urology 2004 63 : 103 9.
22. Bhatnagar V, Stewart ST, Huynh V, et al. Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment. Prostate Cancer Prostatic Dis 2006 9 : 136 46.
23. Albertsen PC. Who needs to be treated? Mol Urol 1999 3 : 183 90.
24. Blute ML, Bergstralh EJ, Iocca A, et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001 165 : 119 25.
25. Sandler HM, Dunn RL, McLaughlin PW, et al. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 2000 48 : 629 33.
26. Horwich A, Parker CC, Huddart RA, Dearnaley DP. Management of early prostate cancer. Ann Oncol 2002 13 : 83 7.
27. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002 347 : 781 9.
28. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005 352 : 1977 84.
29. Albertsen PC. Early-stage prostate cancer. When is observation appropriate? Hematol Oncol Clin North Am 1996 10 : 611 25.
30. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 281 : 1591 7.
31. Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999 353 : 267 72.
32. Kupelian PA, Elshaikh M, Reddy CA, et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002 20 : 3376 85.
33. Arai Y. Radical prostatectomy: time trends, morbidity and quality of life. Int J Urol 2001 8 (Suppl S15 8.
34. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002 347 : 790 6.
35. Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001 19 : 3750 7.
36. Litwin MS, Melmed GY, Nakazon T. Life after radical prostatectomy: a longitudinal study. J Urol 2001 166 : 587 92.
37. Fowler FJ Jr., Barry MJ, Lu-Yao G, et al. Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. J Clin Oncol 1996 14 : 2258 65.
38. Madalinska JB, Essink-Bot ML, de Koning HJ, et al. Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment. Prostate 2001 46 : 87 97.
39. Lim AJ, Brandon AH, Fiedler J, et al. Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. J Urol 1995 154 : 1420 5.
40. Hamilton AS, Stanford JL, Gilliland FD, et al. Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001 19 : 2517 26.
41. Storey MR, Pollack A, Zagars G, et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000 48 : 635 42.
42. Fransson P, Damber JE, Tomic R, et al. Quality of life and symptoms in a randomized trial of radiotherapy versus deferred treatment of localized prostate carcinoma. Cancer 2001 92 : 3111 9.
43. Zelefsky MJ, Cowen D, Fuks Z, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999 85 : 2460 8.
44. Smith DS, Carvalhal GF, Schneider K, et al. Quality-of-life outcomes for men with prostate carcinoma detected by screening. Cancer 2000 88 : 1454 63.
45. McCammon KA, Kolm P, Main B, Schellhammer PF. Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer. Urology 1999 54 : 509 16.
46. Shrader-Bogen CL, Kjellberg JL, McPherson CP, Murray CL. Quality of life and treatment outcomes: prostate carcinoma patients' perspectives after prostatectomy or radiation therapy. Cancer 1997 79 : 1977 86.
47. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000 283 : 354 60.
48. Jonler M, Nielsen OS, Wolf H. Urinary symptoms, potency, and quality of life in patients with localized prostate cancer followed up with deferred treatment. Urology 1998 52 : 1055 62 discussion 1063.
49. Althof SE. Quality of life and erectile dysfunction. Urology 2002 59 : 803 10.
50. Krane RJ. Urinary incontinence after treatment for localized prostate cancer. Mol Urol 2000 4 : 279 86 discussion 287.
51. Rabbani F, Stapleton AM, Kattan MW, et al. Factors predicting recovery of erections after radical prostatectomy. J Urol 2000 164 : 1929 34.
52. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998 280 : 975 80.
53. Yan Y, Carvalhal GF, Catalona WJ, Young JD. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer 2000 88 : 1122 30.
54. Harlan LC, Potosky A, Gilliland FD, et al. Factors associated with initial therapy for clinically localized prostate cancer: Prostate Cancer Outcomes Study. J Natl Cancer Inst 2001 93 : 1864 71.
55. Souchek J, Stacks JR, Brody B, et al. A trial for comparing methods for eliciting treatment preferences from men with advanced prostate cancer: results from the initial visit. Med Care 2000 38 : 1040 50.
56. Stewart ST, Lenert L, Bhatnagar V, Kaplan RM. Utilities for prostate cancer health states in men aged 60 and older. Med Care 2005 43 : 347 55.
57. Gafni A, Birch S, Mehrez A. Economics, health and health economics: HYEs (healthy-years equivalent) versus QALYs (quality-adjusted live-year). J Health Econ 1993 12 : 325 39.
58. Mehrez A, Gafni A. Healthy-years equivalents versus quality-adjusted life years: in pursuit of progress. Med Decis Making 1993 13 : 287 92.